Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
The pharmacokinetics of amifostine, a protector against chemotherapy and radiation-induced toxicities, was investigated in the plasma and ascites of a cancer patient. A high-performance liquid chromatography (HPLC) procedure with electrochemical detection was used to measure amifostine, its active metabolite, WR 1065, and the disulfides (symmetrical plus mixed disulfides). Both amifostine and WR 1065 were rapidly cleared from the plasma (95% and 50% of the peak concentration within 1 h, respectively). The disulfides, which were rapidly formed from WR 1065, were cleared much more slowly (final half-life 13.6 h). Multiple dosing resulted in a tendency toward increasing peak levels of WR 1065 and decreasing peak levels of the disulfides. Only 1% of the delivered dose appeared in the ascites. Therefore, it is not plausible that the presence of ascites or other third spaces would have an impact on the pharmacokinetics of amifostine.
Korst
A E
AE
University Hospital Vrije Universiteit, Clinical Research Laboratory of Oncology, Amsterdam, The Netherlands.
Gall
H E
HE
Vermorken
J B
JB
van der Vijgh
W J
WJ
D000230:Adenocarcinoma / Q000378:metabolism*; D004999:Amifostine / Q000378:metabolism / Q000493:pharmacokinetics*; D001201:Ascites / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004220:Disulfides / Q000097:blood; D006207:Half-Life; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008624:Mercaptoethylamines / Q000493:pharmacokinetics; D008875:Middle Aged; D011837:Radiation-Protective Agents / Q000378:metabolism / Q000493:pharmacokinetics*; D013274:Stomach Neoplasms / Q000378:metabolism*
D004220:Disulfides; D008624:Mercaptoethylamines; D011837:Radiation-Protective Agents; C020174:N-(2-mercaptoethyl)-1,3-diaminopropane; D004999:Amifostine